Clinical Trials Browser

Phase 2/3 × Leukemia, Myeloid, Acute × ibrutinib × Clear all

NCT03642236 2018-08-22

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Phase 2/3 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute